Syon Capital LLC Has $486,000 Stock Holdings in Agilent Technologies, Inc. (NYSE:A)

Syon Capital LLC lifted its position in shares of Agilent Technologies, Inc. (NYSE:A) by 83.4% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 3,498 shares of the medical research company’s stock after purchasing an additional 1,591 shares during the quarter. Syon Capital LLC’s holdings in Agilent Technologies were worth $486,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds also recently made changes to their positions in the company. OFI Invest Asset Management bought a new position in Agilent Technologies in the third quarter valued at approximately $25,000. MV Capital Management Inc. raised its holdings in shares of Agilent Technologies by 120.7% during the fourth quarter. MV Capital Management Inc. now owns 192 shares of the medical research company’s stock worth $27,000 after acquiring an additional 105 shares during the period. Baystate Wealth Management LLC lifted its position in Agilent Technologies by 107.3% in the 4th quarter. Baystate Wealth Management LLC now owns 257 shares of the medical research company’s stock valued at $36,000 after acquiring an additional 133 shares in the last quarter. Column Capital Advisors LLC boosted its stake in Agilent Technologies by 1,111.1% in the 3rd quarter. Column Capital Advisors LLC now owns 327 shares of the medical research company’s stock worth $37,000 after purchasing an additional 300 shares during the period. Finally, Rosenberg Matthew Hamilton increased its holdings in Agilent Technologies by 51.1% during the 4th quarter. Rosenberg Matthew Hamilton now owns 284 shares of the medical research company’s stock worth $39,000 after purchasing an additional 96 shares in the last quarter. Institutional investors and hedge funds own 87.42% of the company’s stock.

Agilent Technologies Trading Up 1.0 %

A stock opened at $137.69 on Friday. Agilent Technologies, Inc. has a one year low of $96.80 and a one year high of $151.58. The stock has a market cap of $40.35 billion, a price-to-earnings ratio of 32.78, a price-to-earnings-growth ratio of 4.17 and a beta of 1.11. The company has a fifty day moving average price of $141.59 and a two-hundred day moving average price of $130.56. The company has a debt-to-equity ratio of 0.41, a current ratio of 2.68 and a quick ratio of 2.04.

Agilent Technologies (NYSE:A) last announced its earnings results on Tuesday, February 27th. The medical research company reported $1.29 EPS for the quarter, topping the consensus estimate of $1.22 by $0.07. The business had revenue of $1.66 billion during the quarter, compared to the consensus estimate of $1.59 billion. Agilent Technologies had a net margin of 18.35% and a return on equity of 27.09%. Agilent Technologies’s revenue was down 5.5% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $1.37 EPS. Equities analysts anticipate that Agilent Technologies, Inc. will post 5.5 EPS for the current year.

Agilent Technologies Dividend Announcement

The company also recently announced a quarterly dividend, which was paid on Wednesday, April 24th. Stockholders of record on Tuesday, April 2nd were paid a dividend of $0.236 per share. The ex-dividend date of this dividend was Monday, April 1st. This represents a $0.94 dividend on an annualized basis and a dividend yield of 0.69%. Agilent Technologies’s dividend payout ratio (DPR) is currently 22.38%.

Insider Buying and Selling

In other news, VP Rodney Gonsalves sold 4,828 shares of the business’s stock in a transaction dated Thursday, March 7th. The shares were sold at an average price of $149.00, for a total value of $719,372.00. Following the completion of the sale, the vice president now owns 21,329 shares of the company’s stock, valued at $3,178,021. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. In other news, VP Rodney Gonsalves sold 4,828 shares of Agilent Technologies stock in a transaction that occurred on Thursday, March 7th. The shares were sold at an average price of $149.00, for a total value of $719,372.00. Following the completion of the sale, the vice president now directly owns 21,329 shares in the company, valued at $3,178,021. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. Also, CEO Michael R. Mcmullen sold 52,297 shares of the business’s stock in a transaction that occurred on Friday, March 8th. The shares were sold at an average price of $150.00, for a total value of $7,844,550.00. Following the completion of the sale, the chief executive officer now owns 253,909 shares of the company’s stock, valued at $38,086,350. The disclosure for this sale can be found here. In the last ninety days, insiders sold 61,610 shares of company stock valued at $9,220,333. Insiders own 0.33% of the company’s stock.

Wall Street Analysts Forecast Growth

A has been the subject of a number of recent research reports. Stifel Nicolaus raised Agilent Technologies from a “hold” rating to a “buy” rating and upped their price target for the stock from $145.00 to $163.00 in a research report on Friday, April 5th. UBS Group raised their target price on shares of Agilent Technologies from $130.00 to $155.00 and gave the company a “neutral” rating in a research report on Wednesday, February 28th. Evercore ISI lifted their price target on shares of Agilent Technologies from $132.00 to $145.00 and gave the company an “in-line” rating in a research note on Thursday, April 4th. Citigroup increased their price objective on shares of Agilent Technologies from $130.00 to $145.00 and gave the stock a “neutral” rating in a research note on Wednesday, February 28th. Finally, Barclays raised their price objective on Agilent Technologies from $125.00 to $135.00 and gave the company an “underweight” rating in a report on Wednesday, April 10th. One investment analyst has rated the stock with a sell rating, five have assigned a hold rating and twelve have assigned a buy rating to the company’s stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $141.29.

Agilent Technologies Profile

Agilent Technologies, Inc provides application focused solutions to the life sciences, diagnostics, and applied chemical markets worldwide. The company operates in three segments: Life Sciences and Applied Markets, Diagnostics and Genomics, and Agilent CrossLab. The Life Sciences and Applied Markets segment offers liquid chromatography systems and components; liquid chromatography mass spectrometry systems; gas chromatography systems and components; gas chromatography mass spectrometry systems; inductively coupled plasma mass spectrometry instruments; atomic absorption instruments; microwave plasma-atomic emission spectrometry instruments; inductively coupled plasma optical emission spectrometry instruments; raman spectroscopy; cell analysis plate based assays; flow cytometer; real-time cell analyzer; cell imaging systems; microplate reader; laboratory software; information management and analytics; laboratory automation and robotic systems; dissolution testing; and vacuum pumps, and measurement technologies.